Atopic Dermatitis Market Overview, Analysis And Demand By 2034

Tailored for companies operating in or entering the atopic dermatitis sector, this analysis highlights core growth drivers, risks, and innovation trends.

How Fast Is The Atopic Dermatitis Market Growing Towards 2025?
The atopic dermatitis market size has grown rapidly in recent years. It will grow from $8.61 billion in 2024 to $9.88 billion in 2025 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to medical understanding and awareness, incidence and prevalence rates, patient advocacy and support, treatment options evolution, research and development.

The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $17.08 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to biologic therapies advancements, immunomodulators and small molecule drugs, pediatric-specific treatments, gene therapy and precision medicine, digital health integration. Major trends in the forecast period include technological advancements in topicals, pediatric ad care focus, environmental and allergen management, precision diagnosis tools.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8285&type=smp

Atopic Dermatitis Market Drivers And Opportunities
The high prevalence of atopic dermatitis is expected to propel the growth of the atopic dermatitis market forward. Atopic dermatitis, also called eczema, is a skin condition that causes dryness and itchiness of the skin. The increasing prevalence of atopic dermatitis increases the need for diagnosis and treatment of the disease. For instance, according to Oxford Academic, a UK-based publishing company, atopic dermatitis (AD) is widely prevalent across the globe, affecting approximately 2.6% of the world's population, equating to about 204 million people in 2024. This figure comprises about 101 million adults and 103 million children. Therefore, the increasing prevalence of atopic dermatitis is driving the growth of the atopic dermatitis market.

How Is The Atopic Dermatitis Market Segmented?
The atopic dermatitismarket covered in this report is segmented –

1) By Drug Class: Corticosteroids; Emollients Or Moisturizers; IL-4 And PDE4 Inhibitors; Calcineurin Inhibitors; Antibiotics; Other Drug Classes
2) By Mode of Administration: Topical; Injectable; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:
1) By Corticosteroids: Topical Corticosteroids; Systemic Corticosteroids
2) By Emollients Or Moisturizers: Creams and Lotions; Ointments and Balms; Barrier Repair Creams
3) By IL-4 And PDE4 Inhibitors: Dupilumab (IL-4 Inhibitor); Apremilast (PDE4 Inhibitor)
4) By Calcineurin Inhibitors: Tacrolimus Ointment; Pimecrolimus Cream
5) By Antibiotics: Topical Antibiotics; Systemic Antibiotics
6) By Other Drug Classes: Antihistamines; Biologics; JAK Inhibitors

What Are The Future Trends Of The Atopic Dermatitis Market?
Product innovations are a key trend gaining popularity in the atopic dermatitis market. Major companies in the market are introducing innovative products to strengthen their market position. For instance, in June 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company received FDA approval for Dupixent (dupilumab). Dupixent is used for children with moderate-to-severe atopic dermatitis, ages 6 months to 5 years. Topical corticosteroids can be used with or without dupixent. Dupixent functions by inhibiting the signaling of two major Type 2 inflammatory sources (IL-4 and IL-13), which are crucial in the development of eosinophilic esophagitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and asthma .

Major Companies Operating In The Atopic Dermatitis Market Are:
Major companies operating in the atopic dermatitis market are Sanofi SA, Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, F Hoffmann-La Roche AG, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Mylan MV, Allergan PLC, Encore Dermatology Inc., Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Roche Holding AG, Valeant Pharmaceuticals International Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Gilead Sciences Inc., Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited

View the full atopic dermatitis market report here:
https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Regional Analysis: Opportunities And Challenges In The Atopic Dermatitis Market
North America was the largest region in the atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company